



The Company

Stem Sel® srl, a new firm for cellular biotechnologies

Today cellular biotechnology can rely on a brand new Italian excellence: Stem Sel. We present an innovative and efficient method to select stem cells. We are a university spinoff founded in November 2013. Its core activity is based on creating and developing novel proprietary technologies to decline them into products able to select stem cells from adult tissues with the highest potential, also for future medical use.

Our first product, the brand new device Celector®, will significantly improve applications in the field of cellular biotechnologies targeted to stem cell therapies.

Celector®, the revolutionary idea

Celector® is our first product based on our proprietary methodology that isolates and sorts stem cells without immunotags. The novel methodology “collects” cells due to their physical differences only. This absence of immunotags is the unique feature of Celector® and it avoids possible cell alteration, and it helps cells keeping their native, regenerative power.

Novelty and unique features of Celector® make Stem Sel a potential leader in the industry of technologies and tools for cell treatments. Celector® aims to change the operational framework of stem cell characterization and production in R&D labs, cell banks, cell factories and, in the future, in clinics.

Stem cells, a booming market

The stem cell market is constantly expanding, also because of the progressive aging of population. Such an expansion comes together with the increasing incomes of the “emerging economies” (firstly, Asian countries). The use of stem cells is also increasingly requested by pharmaceutical industry to develop and test new pharmaceuticals.

Recent forecasts show an increase of the stem cell market of more than 25%, with a business worth 120 billion dollars by 2018. Within the stem cell market, the sector of technologies and tools for cell treatment is also rapidly increasing, and it is expected to reach a global turnover of 2.5 billion dollars in two years. Stem Sel is well positioned in the global market and, if properly supported, it might soon reach a leading position.



Awards

(2012) 1st position at StartCup 2013, business plan competition won by Stem Sel between 52 projects, selected by investors and a committee of experts in high technology content companies.

(2012) UK Trade Investment's UKIT Entrepreneur Award for business internationalization.

(2012) ItaliaCamp - Celector is winning idea of regional phase, and it was presented January 2014 to the Presidency of Government Council at the event "Your Idea for the Country".

(2013) Intel Business Challenge's European phase.

"... talk about Celector®", at Rizzoli Orthopaedic Institute (IOR), Bologna, Italy

Laboratory of Biomechanics & Technological Innovation: *"...no one actually knows exactly what and how much you inject in cell treatments, while the quantity and quality of MSCs is a fundamental condition. It's essential that cells are not marked. Celector® would have a decisive advantage compared to competitors..."*.

PROMETEO Lab: *"...using Celector® the quality of cells will be better than the ones obtained by reference techniques using tag or enzymes. When Celector® will be available, it will be an interesting tool for tissue banks..."*.

RAMSES Lab: *"...whoever does experiments knows that it is essential to maintain cells unmanipulated to observe cellular responses. This is one of the main reasons for the interest in technologies for tag-less cell enrichment.*

Applying Celector® with stem cells is significant, because alternatives are based on immunolabeling. Costs should be an additional advantage of using Celector®...".

Team

Founders: Prof. Pierluigi Reschiglian, *President/CEO*
Prof. Barbara Roda, *CTO*
Prof. Andrea Zattoni, *CFO*
Kristel Martinelli
Incubator (AlmaCube Ltd)
Investors

R&D: Marco Vaglivello, *Product Manager*
Ilaria Vigliotta, *Product Specialist*
Silvia Zia, *R&D Specialist*
Martina Rossi, *Biotechnologist*
Fabio Gnudi, *HW&SW Manager*